Valentis to merge with Urigen

Burlingame, CA-based Valentis announced that it would merge with Urigen through a stock swap. The company has been in a downward spiral since the drug developer announced that a Phase IIb trial of its lead drug candidate for peripheral arterial disease failed to show any advantage over a placebo. Valentis decided not to further develop the drug. Urigen, also based in Burlingame, is a privately-held specialty pharmaceutical focused on urology. Urigen will become a wholly-owned subsidiary of Valentis.

"The merger of Valentis and Urigen will create a new specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. The combined company will offer an attractive portfolio of products in clinical development," said Benjamin F. McGraw, III, Chairman, President and CEO of Valentis in a press release. The company is anticipating Phase IIb from another drug candidate at the end of this year.

- here's the report on the merger from The San Francisco Business Times

Related Article
Valentis future in doubt after Phase IIb failure. Report
Layoffs reported at Valentis. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.